Ā | nā=ā137 |
---|---|
Age (meanāĀ±āSD, years) | 53.83āĀ±ā11.60 |
Body mass index (meanāĀ±āSD, kg/m2) | 24.82āĀ±ā7.25 |
Age of menarche (meanāĀ±āSD, years) | 18.81āĀ±ā0.71 |
Postmenopausal status | 65 (47.45) |
Marital status | |
āMarried | 106 (77.37) |
āSingle | 25 (18.25) |
āDivorced | 6 (4.38) |
Number of children | |
ā0 | 16 (11.68) |
ā1 | 18 (13.14) |
ā2 | 73 (53.28) |
āā>ā3 | 30 (21.90) |
Family history of breast or ovarian cancer | 6 (4.38) |
History of hormone replacement therapy | |
āNo | 134 (97.81) |
āYes | 3 (2.19) |
Location of tumor | |
āRight | 76 (55.48) |
āLeft | 61 (44.53) |
Types of tumor | |
āDuctal carcinoma in situ | 21 (15.33) |
āInvasive ductal carcinoma | 112 (81.76) |
āInvasive lobular carcinoma | 1 (0.73) |
āOther | 3 (2.19) |
Pathologic stage | |
ā0 | 22 (16.06) |
āIA | 66 (48.18) |
āIIA | 25 (18.25) |
āIIB | 15 (10.95) |
āIIIA | 7 (5.11) |
āIIIC | 2 (1.46) |
Estrogen receptor | |
āPositive | 119 (86.87) |
āNegative | 18 (13.14) |
Progesterone receptor | |
āPositive | 102 (74.46) |
āNegative | 35 (25.55) |
Her2/neu gene | |
āPositive | 24 (17.52) |
āNegative | 113 (82.49) |
Triple negative breast cancer | 17 (12.41) |
Ki67 index | |
āāā„ā15% | 100 (73.00) |
āā<ā15% | 37 (27.01) |
Type of breast surgery | |
āBreast conserving surgery | 98 (71.54) |
āMastectomy | 39 (28.47) |
āBreast reconstruction | 42 (30.66) |
Type of axillary surgery | |
āNo operation | 4 (2.92) |
āSentinel lymph nodes biopsy | 119 (86.87) |
āAxillary lymph nodes dissection | 14 (10.22) |
Adjuvant chemotherapy | 62 (45.26) |
Adjuvant radiotherapy | 97 (70.81) |
Adjuvant hormonal therapy | 93 (67.89) |
Follow-up period (meanāĀ±āSD, months) | 8.01āĀ±ā0.69 |